Loading...
•
Dec 31, 2023
Celldex Q4 2023 Earnings Report
Reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
Key Takeaways
Celldex Therapeutics reported Q4 2023 financial results, with a total revenue of $4.1 million and a net loss of $43.3 million, or ($0.83) per share. Cash, cash equivalents, and marketable securities as of December 31, 2023, were $423.6 million. The company believes its current financial resources are sufficient to fund planned operations into 2026.
Total revenue was $4.1 million in the fourth quarter of 2023.
Research and development expenses were $30.4 million in the fourth quarter of 2023.
General and administrative expenses were $8.8 million in the fourth quarter of 2023.
Net loss was $43.3 million, or ($0.83) per share, for the fourth quarter of 2023.
Revenue by Segment
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2023 are sufficient to meet estimated working capital requirements and fund current planned operations into 2026.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...